High-grade astrocytoma with piloid features (HGAP)

View Details
Status
Done

General

  • First tumours to be defined by a specific methylation profile
  • Aka: methylation-class anaplastic astrocytoma with piloid features (MC-AAP)

Definition

  • Essential:
    • An astrocytic glioma AND
    • A DNA methylation profile of high-grade astrocytoma with piloid features
  • Desirable:
    • МАРК pathway gene alteration
    • Homozygous deletion or mutation of CDKN2A and/or CDKN2B, or amplification of CDK4
    • Mutation of ATRX or loss of nuclear ATRX expression
    • Anaplastic histological features

Numbers

  • Adult population with a median patient age of 40 years (4–88 years)

Pathology

  • A mixture of histological features including those of a high-grade astrocytoma/glioblastoma and pilocytic-like features.

Genetic

  • Alterations of the MAPK pathway are frequently combined with homozygous deletion in CDKN2A, CDKN2B, and/or ATRX mutations.

Grading

  • More data are required to confirm a CNS WHO grade but current evidence suggests a clinical behaviour similar to grade 3.

Location

  • Posterior fossa with the cerebellum being the most common site (74%).
    • Recently, a reanalysis of cerebellar GBMs by methylation array revealed a moderately high proportion of HGAPs (25 of 86 patients)

Radiology

  • Given that this is a newly recognised type, its radiological features and clinical characteristics are still emerging.

Imaging

  • Rim enhancement with lack of central enhancement
  • Hyperintense appearance on T2w
  • Diffusion restriction and cyst formation did not appear to be features
  • O-(2-[18F] fluoroethyl)-l-tyrosine positron emission tomography might be a useful tool for this tumour type.
  • Limited paediatric population descriptions
    • Nevertheless, they described a single case of HGAP in an 8-year-old girl with a parietal tumour who underwent resection followed by chemoradiotherapy and had an overall survival of 37 months [95]. Like PA, there does appear to be an association between HGAP and NF1

Prognosis

  • Poor prognosis
    • Marginally better than IDH-wildtype GBMs
    • Comparable to that of IDH-mutant astrocytoma